Journal
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Volume 20, Issue 11, Pages 720-723Publisher
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clml.2020.06.014
Keywords
Allogeneic stem cell transplantation; COVID-19; Graft-versus-host disease; Immunocompromised; JAK inhibitor
Categories
Ask authors/readers for more resources
Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has a high death rate in patients with comorbidities or in an immunocompromised state. We report a mild and attenuated SARS CoV-2 infection in a patient who is 17 months post stem cell transplantation and maintained on the JAK/STAT inhibitor ruxolitinib, a proposed novel therapy for SARS CoV-2 pneumonia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available